Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Comparative pharmacokinetics of levamisole-oxyclozanide combination in sheep and goats following per os administration
whereas the CYM-5520 is an agonist with an EC50 of 1
CDK2/cyclinE
2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety
5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3
VU0364572 (trifluoroacetate salt) 247egeline Comparative pharmacokinetics of levamisole-oxyclozanide combinationIC50: 477 172 nM VU0364572 is a M1 agonist. Alzheimer's disease (AD) is the leading cause of dementia worldwide, and no disease modifying therapy is availables. Selective M1 muscarinic acetylcholine receptor activation is an attractive mechanism for AD therapy since M1 mediates key effects on cognition, memory, and behavior and has potential for disease modifying effects on A formation and tau phosphorylation. In vitro: Previous study found that